UPCC 44419: Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (AML)

Brief description of study

The purpose of this study is to compare the effectiveness of gilteritinib to midostaurin in patients receiving standard combination chemotherapy for FLT3 AML. Eligible untreated patients with FLT3 acute myeloid leukemia (AML) between the ages of 18 and 65 will be randomized to receive gilteritinib or midostaurin during induction and consolidation. Patients will also receive standard chemotherapy of daunorubicin and cytarabine during induction and high-dose cytarabine during consolidation.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Acute Myeloid Leukemia, AML, cancer, oncology
  • Age: Between 18 Years - 99 Years
  • Gender: All
Updated on 18 Feb 2020. Study ID: 834417

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center